The Prognostic and therapeutic value and clinical implications of fibroblast activation protein-α as a novel biomarker in colorectal cancer

Cell Commun Signal. 2023 Jun 14;21(1):139. doi: 10.1186/s12964-023-01151-y.

Abstract

The identification of contributing factors leading to the development of Colorectal Cancer (CRC), as the third fatal malignancy, is crucial. Today, the tumor microenvironment has been shown to play a key role in CRC progression. Fibroblast-Activation Protein-α (FAP) is a type II transmembrane cell surface proteinase expressed on the surface of cancer-associated fibroblasts in tumor stroma. As an enzyme, FAP has di- and endoprolylpeptidase, endoprotease, and gelatinase/collagenase activities in the Tumor Microenvironment (TME). According to recent reports, FAP overexpression in CRC contributes to adverse clinical outcomes such as increased lymph node metastasis, tumor recurrence, and angiogenesis, as well as decreased overall survival. In this review, studies about the expression level of FAP and its associations with CRC patients' prognosis are reviewed. High expression levels of FAP and its association with clinicopathological factors have made as a potential target. In many studies, FAP has been evaluated as a therapeutic target and diagnostic factor into which the current review tries to provide a comprehensive insight. Video Abstract.

Keywords: Cancer-associated fibroblasts; Colorectal cancer; Fibroblast activation protein; Tumor microenvironment.

Publication types

  • Video-Audio Media
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Colorectal Neoplasms* / diagnosis
  • Endopeptidases*
  • Humans
  • Prognosis
  • Tumor Microenvironment

Substances

  • fibroblast activation protein alpha
  • Biomarkers
  • Endopeptidases